EA201390958A1 - АКТИВНЫЕ ПРОТЕАЗОУСТОЙЧИВЫЕ МУТАНТЫ АНТИТЕЛ Fc - Google Patents

АКТИВНЫЕ ПРОТЕАЗОУСТОЙЧИВЫЕ МУТАНТЫ АНТИТЕЛ Fc

Info

Publication number
EA201390958A1
EA201390958A1 EA201390958A EA201390958A EA201390958A1 EA 201390958 A1 EA201390958 A1 EA 201390958A1 EA 201390958 A EA201390958 A EA 201390958A EA 201390958 A EA201390958 A EA 201390958A EA 201390958 A1 EA201390958 A1 EA 201390958A1
Authority
EA
Eurasian Patent Office
Prior art keywords
proteousstable
mutants
antibodies
active
containing molecules
Prior art date
Application number
EA201390958A
Other languages
English (en)
Other versions
EA028658B1 (ru
Inventor
Уилльям Строл
Роберт Джордан
Рэндалл Брезски
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA201390958A1 publication Critical patent/EA201390958A1/ru
Publication of EA028658B1 publication Critical patent/EA028658B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Моноклональное антитело и другие Fc-содержащие молекулы могут конструироваться с использованием раскрытых вариаций в участке Fc, обеспечивающих повышенную устойчивость к протеазам хозяина и патогена и показывающих способность взаимодействовать с рецепторами Fcγ и инициировать комплементнаправленную цитотоксичность, что подтверждается результатами функциональных анализов. Fc-содержащие молекулы применяются для лечения различных заболеваний и расстройств, при которых активности способствуют определяемые FcR функции клетки-хозяина.
EA201390958A 2010-12-23 2011-12-15 МОДИФИЦИРОВАННАЯ ПРОТЕАЗОУСТОЙЧИВАЯ Fc-СОДЕРЖАЩАЯ МОЛЕКУЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ВКЛЮЧАЮЩИЕ ЕЕ ИСПОЛЬЗОВАНИЕ EA028658B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201061426619P 2010-12-23 2010-12-23
US61/426,619 2010-12-23
US201161540882P 2011-09-29 2011-09-29
US61/540,882 2011-09-29
PCT/US2011/065174 WO2012087746A1 (en) 2010-12-23 2011-12-15 Active protease-resistant antibody fc mutants

Publications (2)

Publication Number Publication Date
EA201390958A1 true EA201390958A1 (ru) 2013-11-29
EA028658B1 EA028658B1 (ru) 2017-12-29

Family

ID=46314374

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390958A EA028658B1 (ru) 2010-12-23 2011-12-15 МОДИФИЦИРОВАННАЯ ПРОТЕАЗОУСТОЙЧИВАЯ Fc-СОДЕРЖАЩАЯ МОЛЕКУЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ВКЛЮЧАЮЩИЕ ЕЕ ИСПОЛЬЗОВАНИЕ

Country Status (31)

Country Link
US (2) US8871204B2 (ru)
EP (1) EP2654780B1 (ru)
JP (1) JP6012624B2 (ru)
KR (1) KR101900280B1 (ru)
CN (1) CN103260640B (ru)
AU (1) AU2011349719B2 (ru)
BR (1) BR112013018317A2 (ru)
CA (1) CA2822366A1 (ru)
CO (1) CO6741179A2 (ru)
CR (1) CR20130292A (ru)
CY (1) CY1118923T1 (ru)
DK (1) DK2654780T3 (ru)
EA (1) EA028658B1 (ru)
EC (1) ECSP13012712A (ru)
ES (1) ES2623912T3 (ru)
GT (1) GT201300167A (ru)
HR (1) HRP20170595T1 (ru)
HU (1) HUE033205T2 (ru)
IL (1) IL226987A (ru)
LT (1) LT2654780T (ru)
MX (1) MX347077B (ru)
MY (1) MY162489A (ru)
NI (1) NI201300057A (ru)
NZ (1) NZ612379A (ru)
PL (1) PL2654780T3 (ru)
PT (1) PT2654780T (ru)
RS (1) RS55906B1 (ru)
SG (1) SG191233A1 (ru)
SI (1) SI2654780T1 (ru)
WO (1) WO2012087746A1 (ru)
ZA (1) ZA201305538B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
MY162489A (en) * 2010-12-23 2017-06-15 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY Fc MUTANTS
ES2746052T3 (es) 2011-06-28 2020-03-04 Inhibrx Lp Polipéptidos de fusión de serpina y métodos de uso de los mismos
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
AU2013218017B2 (en) 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2833162T5 (es) * 2014-07-16 2024-06-12 Hinrich Abken Receptor de antígeno quimérico y su uso
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
RU2746804C2 (ru) 2014-10-10 2021-04-21 Иннейт Фарма Блокада cd73
AU2015339507B2 (en) * 2014-10-27 2021-07-01 Inhibrx, Inc. Serpin fusion polypeptides and methods of use thereof
EP3221359B1 (en) 2014-11-17 2020-05-27 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
JP6773679B2 (ja) 2015-03-30 2020-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
WO2016197071A1 (en) 2015-06-05 2016-12-08 New York University Compositions and methods for anti-staphylococcal biologic agents
RU2737378C2 (ru) * 2015-07-24 2020-11-27 Гликник Инк. Гибридные белки фрагментов белков человека для создания упорядоченно мультимеризованных композиций областей fc иммуноглобулинов с усиленным связыванием с системой комплемента
PE20180802A1 (es) 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos
CN108368510B (zh) 2015-09-30 2023-09-01 詹森生物科技公司 特异性结合人cd40的激动性抗体和使用方法
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2017068183A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain cd137-receptor agonist proteins
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
AU2017235274A1 (en) 2016-03-15 2018-08-16 Innate Pharma Anti-mica antibodies
JP7045333B6 (ja) * 2016-05-23 2022-05-06 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法
US20190263918A1 (en) * 2016-06-08 2019-08-29 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
MX2019010848A (es) 2017-03-16 2019-10-30 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
AU2018244574A1 (en) * 2017-03-28 2019-10-31 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
AU2018266847A1 (en) * 2017-05-10 2019-11-28 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual HIV antiviral and immunomodulatory activity
DK3456736T3 (da) 2017-09-19 2021-05-03 Tillotts Pharma Ag Antistofvarianter
SG11202012435UA (en) 2018-06-18 2021-01-28 Innate Pharma Compositions and methods for treating cancer
JP2021535142A (ja) 2018-08-31 2021-12-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略
EP4321530A3 (en) 2018-09-27 2024-05-22 Xilio Development, Inc. Masked cytokine polypeptides
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
US20220380457A1 (en) * 2019-08-23 2022-12-01 City Of Hope Igg antibody compositions and methods of making the same
WO2022031876A1 (en) * 2020-08-07 2022-02-10 Genentech, Inc. Flt3 ligand fusion proteins and methods of use
WO2022167729A1 (en) * 2021-02-04 2022-08-11 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
CN117597365A (zh) * 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
CA2331607A1 (en) 1998-05-06 1999-11-11 Temple University - Of The Commonwealth System Of Higher Education Reversal of proinflammatory response by ligating the macrophage fc.gamma.ri receptor
PL220113B1 (pl) * 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7129331B2 (en) 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2592015A1 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
CA2619825A1 (en) 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations
EP1931709B1 (en) * 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
SG183701A1 (en) * 2007-08-10 2012-09-27 Centocor Ortho Biotech Inc Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
CA2700394C (en) 2007-09-26 2017-10-24 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2637918T3 (es) 2007-09-28 2017-10-17 Janssen Biotech, Inc. Métodos y conformaciones estructurales de preparaciones de anticuerpos con aumento de la resistencia a las proteasas
EP2211904B1 (en) * 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
US20120039880A1 (en) 2009-04-21 2012-02-16 Amgen Inc. FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES
MY162489A (en) * 2010-12-23 2017-06-15 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY Fc MUTANTS
US8729985B2 (en) 2012-01-23 2014-05-20 Electro-Mechanical Corporation Switchgear visible disconnect mechanical interlock

Also Published As

Publication number Publication date
EP2654780B1 (en) 2017-02-01
BR112013018317A2 (pt) 2017-03-21
PT2654780T (pt) 2017-04-06
EP2654780A4 (en) 2015-03-18
IL226987A (en) 2017-07-31
DK2654780T3 (en) 2017-04-10
AU2011349719B2 (en) 2016-09-15
GT201300167A (es) 2014-09-26
RS55906B1 (sr) 2017-09-29
CY1118923T1 (el) 2018-01-10
PL2654780T3 (pl) 2017-07-31
CN103260640B (zh) 2015-12-02
NI201300057A (es) 2014-02-25
ECSP13012712A (es) 2013-08-30
KR20140003485A (ko) 2014-01-09
US9611328B2 (en) 2017-04-04
EP2654780A1 (en) 2013-10-30
US8871204B2 (en) 2014-10-28
US20130011386A1 (en) 2013-01-10
KR101900280B1 (ko) 2018-11-08
CO6741179A2 (es) 2013-08-30
WO2012087746A1 (en) 2012-06-28
LT2654780T (lt) 2017-03-27
MX2013007291A (es) 2013-09-13
HRP20170595T1 (hr) 2017-06-16
MY162489A (en) 2017-06-15
CR20130292A (es) 2013-10-03
SG191233A1 (en) 2013-07-31
ZA201305538B (en) 2015-01-28
US20150139984A1 (en) 2015-05-21
SI2654780T1 (sl) 2017-06-30
AU2011349719A1 (en) 2013-07-04
ES2623912T3 (es) 2017-07-12
EA028658B1 (ru) 2017-12-29
JP2014504301A (ja) 2014-02-20
JP6012624B2 (ja) 2016-10-25
HUE033205T2 (en) 2017-11-28
NZ612379A (en) 2014-10-31
CA2822366A1 (en) 2012-06-28
CN103260640A (zh) 2013-08-21
MX347077B (es) 2017-04-10

Similar Documents

Publication Publication Date Title
EA201390958A1 (ru) АКТИВНЫЕ ПРОТЕАЗОУСТОЙЧИВЫЕ МУТАНТЫ АНТИТЕЛ Fc
EA201890907A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
EA201691304A1 (ru) АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
GB2509260A (en) Anti-complement C1s antibodies and uses thereof
MA32948B1 (fr) Anticorps anti-pd-l1 et leur utilisation pour ameliorer la fonction des lymphocytes t
NZ602734A (en) Therapeutic dll4 binding proteins
GT201300149A (es) Proteinas de union al tnf-a
EA201791984A1 (ru) Способы уменьшения уровня fc-содержащих агентов в сыворотке с применением fcrn-антагонистов
JO3097B1 (ar) الأجسام المضادة c-Met
CL2014000134A1 (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina.
WO2011122011A3 (en) Antibodies with modified affinity to fcrn that promote antigen clearance
AR093183A1 (es) Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
MY163539A (en) Antibody fc variants
EA201400565A1 (ru) Молекулы антител, имеющие специфичность в отношении ох40 человека
DOP2014000017A (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
EA202090031A2 (ru) Человеческие антитела против gfr3 и способы их применения
EA200970113A1 (ru) Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н
EP2548574A4 (en) NEW HUMANIZED MONOCLONAL ANTIBODY ANTI-CD20
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека
EA201071068A1 (ru) Антитела к tyrp1
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
EP4292657A3 (en) Flavivirus neutralizing antibodies and methods of use thereof
WO2014002035A3 (en) A human monoclonal antibody against the vp1 protein of jc virus

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU